Replies to post #126221 on Biotech Values

[DewDiligence]

I don’t follow FURX closely, but the stock might be worth examining for the reasons you mentioned. The pipeline doesn’t seem especially noteworthy; however, I listened to a webcast a few months ago and was impressed with the CEO.

[DewDiligence]

FURX down 5% on phase-2 failure of PPD-10558:

http://finance.yahoo.com/news/Furiex-Announces-Results-bw-2678741181.html?x=0

…top-line results from the Phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia, or SAM. PPD-10558 did not meet its primary efficacy endpoint in this randomized, double-blind, proof-of-concept study. The study enrolled patients with high cholesterol and a prior history of SAM, and evaluated recurrence rates for SAM over a twelve-week treatment period across the following three different treatment regimens: placebo; PPD-10558; and atorvastatin (Lipitor). Patients did not report any significant differences in muscle symptoms, nor did they drop out due to SAM in significantly different percentages, among the three regimens.